If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine injection)
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
BASAGLAR® (insulin glargine injection): Indication
Basaglar is a long-acting human insulin analog indicated to improve glycemic control.
Basaglar is a long-acting human insulin analog indicated to improve glycemic control in
adults and pediatric patients with T1DM, and
adults with T2DM.1
Enclosed Prescribing Information
BASAGLAR® (insulin glargine injection), for subcutaneous use, Lilly
1. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Glossary
Basaglar = Basaglar® (insulin glargine injection) 100 units/mL
T1DM = type 1 diabetes mellitus
T2DM = type 2 diabetes mellitus
Date of Last Review: August 05, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
